MSLN Research Reagents

What is MSLN?

MSLN, also known as Mesothelin, is a cell surface glycoprotein encoded by the MSLN gene, anchored to the cell surface by glycosylphosphatidylinositol. This protein was first identified by its reactivity with monoclonal antibody K1. The MSLN protein formation process is as follows: The MSLN gene encodes a proprotein that is proteolytically produced to produce mesothelin and megakaryocyte-potentiating factor (MPF). Mesothelin may play a role in adhesion. Abnormal expression of MSLN plays an important role in tumor cell proliferation, adhesion and drug resistance.

The Structure of MSLN

The MSLN gene was located on chromosome 16 p13.3 with cDNA size of 213 bp. The MSLN gene encodes a precursor protein of 71 KDa. This precursor protein is hydrolyzed into two parts by furin protease: a soluble 31 kDa N-terminal protein called megakaryocyte-potentiating factor (MPF) and a 40 kDa membrane-bound fragment called MSLN.

There are many forms of mesothelin: membrane-bound mesothelin and soluble mesothelin. Soluble mesothelin is a protein of 42-45 kDa, and its NH2-terminal amino acid sequence is identical to membrane-bound mesothelin.

The Expression of MSLN

The name of mesothelin is mainly that the membrane-bound protein encoded by this gene is mainly located on the surface of normal mesothelial cells.

Mesothelin can be expressed in mesothelial cells of the normal pleura, pericardium and peritoneum, and is rarely expressed in normal tissues.

In addition, it is also expressed in a variety of tumor tissues, including mesothelioma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, endometrial cancer, thymic cancer, colon cancer and other tumors.

The Function of MSLN

Mesothelin may play a role in adhesion. With the deepening of research, it has been found to play an important role in the development of various tumors. Aberrant expression of MSLN accelerates cell cycle transition and promotes tumor cell proliferation by regulating cell cycle-associated expression of cyclin E and cyclin-dependent kinase 2 (CDK2). Mesothelin can also increase the tolerance of cancer cells to drugs.

Applications of MSLN in Treatment

Mesothelin is highly expressed in a variety of human malignant cells and is rarely expressed in normal tissues, so mesothelin is expected to be used for tumor-specific therapeutic targets.

Current treatments for MSLN mainly include antibody therapy and CAR-T therapy.

The antibody drugs mainly include Amatuximab (MORAb-009), Anetumab Ravtansine (BAY94-9343), DMOT4039A, MDX-120.

Mesothelin CAR-T therapy has achieved encouraging results in the mouse transplantation model of mesothelioma, ovarian cancer, and lung cancer, and some studies have been in clinical trials.

As a protein with strong immunogenicity, mesothelin can also be used to make anti-tumor vaccines. Soluble mesothelin can also be used as a marker for tumor diagnosis.

Hot Products of MSLN

Recombinant Human Mesothelin(MSLN),partial (Active) (CSB-MP015044HUc9)

The following MSLN reagents supplied by CUSABIO are manufactured under a strict quality control system. Multiple applications have been validated and solid technical support is offered.

MSLN Antibodies

MSLN Antibodies for Mus musculus (Mouse)

MSLN Antibodies for Homo sapiens (Human)

MSLN Proteins

MSLN Proteins for Mus musculus (Mouse)

MSLN Proteins for Rattus norvegicus (Rat)

MSLN Proteins for Homo sapiens (Human)

MSLN ELISA Kit

MSLN ELISA Kit for Homo sapiens (Human)

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1